ArticleBlood advances2022
The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- A qualitative evidence synthesis on perinatal screening for sickle cell disease in high-burden countries.BMC global and public health · 2026Pooled it
- Pooled it
- Incident Stroke in Pediatric Sickle Cell Anemia Despite Overall Improved Transcranial Doppler Velocity in a Ugandan Hydroxyurea Trial: Antecedent and Ongoing Risks.Pediatric blood & cancer · 2025Trial
- Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA).Blood advances · 2026Article
- Hemoglobinopathy diagnostics: the HELIOS Action survey.Blood advances · 2026Article
- The Epidemiology of Sickle Cell Disease in Sub-Saharan Africa: Current Knowledge and Gaps to be Filled.American journal of hematology · 2026Review
- Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa.American journal of hematology · 2026Review
- A maximal-coverage approach to prioritizing newborn sickle cell screening sites in Uganda using a sickle cell-malaria co-risk surface.Malaria journal · 2026Article
- Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.International journal of neonatal screening · 2026Review
- Advances and Gaps in Global Newborn Screening for Sickle Cell Disease.International journal of neonatal screening · 2026Article
- Trends in the burden of sickle cell disorders in Sierra Leone, 1990-2023: An analysis of Global Burden of Disease Study 2023 estimates.PloS one · 2026Article
- Uganda's Mandatory Newborn Sickle Cell Disease Screening Programme: Translating a Decade of Evidence into Differentiated Implementation.Pediatric health, medicine and therapeutics · 2026Article
- Building a Comprehensive Sickle Cell Disease Program in Western Kenya: A Decade of Experience and Growth.Annals of global health · 2026Article
- Early-life clinical and hematological profiles: a comparative study of children with and without sickle cell disease in the first three years of life.Annals of hematology · 2025Article
- Genetic self-counselors in Tunisia: the role of health education in hemoglobinopathies prevention among high school students.Orphanet journal of rare diseases · 2025Article
- Cascade testing effectively identifies undiagnosed sickle cell disease in The Gambia: a quality improvement project.Archives of disease in childhood · 2025Article
- Hemodynamic profile of cerebral arteries using transcranial Doppler in children with sickle cell disease compared to children without sickle cell disease: Prospective analytical study.BMC pediatrics · 2025Article
- Letter to the editor regarding a global overview of sickle cell disease: populations, policy limitations and urgent need for comprehensive SCD clinical care, a systematic review.Journal of sickle cell disease · 2025Article
- Findings supporting neonatal screening for sickle cell disease: an observational study in Senegal.Frontiers in pediatrics · 2025Article
- The status of newborn screening in Africa: Situation analysis, future plans and call to action.African journal of laboratory medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 8 countries.
Funding
Abstract
Sickle cell disease (SCD) is a common condition within sub-Saharan Africa and associated with high under-5 mortality (U5M). The American Society of Hematology instituted the Consortium on Newborn Screening in Africa (CONSA) for SCD, a 7-country network of sites to implement standardized newborn hemoglobinopathy screening and early intervention for children with SCD in sub-Saharan Africa. CONSA's overall hypothesis is that early infant SCD screening and entry into standardized, continuous care will reduce U5M compared with historical estimates in the region. Primary trial objectives are to determine the population-based birth incidence of SCD and effectiveness of early standardized care for preventing early mortality consortium-wide at each country's site(s). Secondary objectives are to establish universal screening and early interventions for SCD within clinical networks of CONSA partners and assess trial implementation. Outcomes will be evaluated from data collected using a shared patient registry. Standardized trial procedures will be implemented among designated birth populations in 7 African countries whose programs met eligibility criteria. Treatment protocol includes administering antibacterial and antimalarial prophylaxis and standard childhood vaccinations against infections commonly affecting children with SCD. Infants with a positive screen and confirmation of SCD within the catchment areas defined by each consortium partner will be enrolled in the clinical intervention protocol and followed regularly until age of 5 years. Effectiveness of these early interventions, along with culturally appropriate family education and counseling, will be evaluated by comparing U5M in the enrolled cohort to estimated preprogram data. Here, we describe the methodology planned for this trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.